申请人:UNITED ARAB EMIRATES UNIVERSITY
公开号:US11091426B1
公开(公告)日:2021-08-17
Cycloalkylamine derivatives may be used for preventing or treating diseases in humans, animals, and have demonstrated efficacy specifically in treating type 2 diabetes. In an embodiment, the cycloalkylamine derivatives can include a compound selected from the group consisting of cycloheptanamine salts, cyclohexanamine salts, cyclopentanamine salts 1-cycloheptyl-[4,4′-bipyridin]-1-ium, N1,N2-dicycloheptyloxalamide, 1-[3′,5′-bis(trifluoromethyl)phenyl]-3-cycloheptylurea, 1,1′-(4-methyl-1,3-phenylene)bis(3-cycloheptylurea), 1-(2′-aminopyrimidin-4′-yl)-3-cycloheptylurea, 4-amino-N-(cycloheptylcarbamoyl)benzenesulfonamide, 4-(3′-cycloheptylureido)-N-(5″-methylisoxazol-3″-yl)benzenesulfonamide, N-(cycloheptylcarbamoyl)-4-methylbenzenesulfonamide, 1-cycloheptylguanidine hydrochloride, (E)-amino[(amino(cycloheptylamino)methylene)amino]methaniminium chloride, or a pharmaceutically acceptable salt thereof.
环丙胺衍生物可用于预防或治疗人类、动物的疾病,并已经在治疗2型糖尿病方面表现出有效性。在一种实施方案中,环丙胺衍生物可以包括从环庚胺盐、环己胺盐、环戊胺盐、1-环庚基-[4,4′-联吡啶]-1-铵、N1,N2-环庚氧草酰胺、1-[3′,5′-双(三氟甲基)苯基]-3-环庚基脲、1,1′-(4-甲基-1,3-苯基)双(3-环庚基脲)、1-(2′-氨基嘧啶-4′-基)-3-环庚基脲、4-氨基-N-(环庚基氨基)苯磺酰胺、4-(3′-环庚基脲基)-N-(5″-甲基异噁唑-3″-基)苯磺酰胺、N-(环庚基氨基)-4-甲基苯磺酰胺、1-环庚基胍盐酸盐、(E)-氨基[(氨基(环庚基氨基)甲亚胺)氯化物],或其药用可接受的盐。